Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 48.20% is 200% above its 5-year average of -48.37%, near the high end of its 5-year range (-94.57%–48.20%).
As of the fiscal period ended Tuesday, June 30, 2026. 351.24% above its 12-month average of -19.19%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 48.20%.
RETURN ON EQUITY (ROE)
48.20%
RETURN ON EQUITY (ROE) AVG TTM
-19.19%
RETURN ON EQUITY (ROE) AVG 3Y
-56.09%
RETURN ON EQUITY (ROE) AVG 5Y
-48.37%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+351.24%
CURRENT VS 3Y AVG
+185.94%
CURRENT VS 5Y AVG
+199.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+214.74%
vs the sector median at left
Rallybio Corporation
Market Cap
$90.64M
Return on Equity (ROE)
48.20%
TTM Avg
-19.19%
3Y Avg
-56.09%
5Y Avg
-48.37%
Market Cap
$90.37M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$90.20M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
Market Cap
$89.78M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
Market Cap
$89.44M
Return on Equity (ROE)
N/A
TTM Avg
329.82%
3Y Avg
69.21%
5Y Avg
21.28%
Market Cap
$87.96M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$87.85M
Return on Equity (ROE)
N/A
TTM Avg
1.45%
3Y Avg
25.22%
5Y Avg
-14.52%
Market Cap
$93.96M
Return on Equity (ROE)
-11.85%
TTM Avg
-51.56%
3Y Avg
-105.39%
5Y Avg
-105.39%
Market Cap
$87.27M
Return on Equity (ROE)
-477.87%
TTM Avg
-156.51%
3Y Avg
-83.51%
5Y Avg
-25.98%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rallybio Corporation (RLYB) | $90.64M | 48.20% | -19.19% | -56.09% | -48.37% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | -268.09% | -238.76% | -155.55% | -124.74% |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 2.51% | -5.84% | -10.75% | -7.81% |
| Equillium, Inc. (EQ)vs › | $89.78M | -32.15% | -60.32% | -93.79% | -79.41% |
| electroCore, Inc. (ECOR)vs › | $89.44M | N/A | 329.82% | 69.21% | 21.28% |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 45.93% | 16.96% | -19.36% | -13.87% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | N/A | 1.45% | 25.22% | -14.52% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.96M | -11.85% | -51.56% | -105.39% | -105.39% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | -477.87% | -156.51% | -83.51% | -25.98% |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $95.14M | -461.14% | -233.39% | -227.67% | -163.94% |
ROE
48.2%
ROA
46.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 48.20% |
| 2026-03-31 | -15.55% |
| 2025-12-31 | -15.49% |
| 2025-09-30 | -22.48% |
| 2025-06-30 | -90.62% |
| 2025-03-31 | -89.11% |
| 2024-12-31 | -93.71% |
| 2024-09-30 | -94.57% |
| 2024-06-30 | -92.33% |
| 2024-03-31 | -85.55% |
| 2023-12-31 | -70.22% |
| 2023-09-30 | -57.07% |
| 2023-06-30 | -50.64% |
| 2023-03-31 | -44.77% |
| 2022-12-31 | -39.37% |
| 2022-09-30 | -47.65% |
| 2022-06-30 | -36.99% |
| 2022-03-31 | -29.59% |
| 2021-12-31 | -26.77% |
| 2021-09-30 | -24.19% |
| 2021-06-30 | -37.35% |
| 2021-03-31 | -29.08% |
| 2020-12-31 | -19.45% |
